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Introduction
The occurrence of distant metastasis is a dreadful complication of breast cancer and a leading cause of death by malignancy in women worldwide. Metastasis is a multi-step process that involves cancer cell migration and invasion across the extracellular matrix to reach the blood flow, followed by extravasation and colonization of secondary organs (1) . Among millions of invasive cancer cells that reach the blood circulation, only few will establish at distant sites and grow as metastases (2) (3) (4) (5) . Breast cancer metastases can remain latent for several years following primary tumor removal, and the identification of molecular markers that may predict the risk of metastasis occurrence and/or progression is of invaluable help for the follow-up of the patients and choice of therapeutic options (5, 6) . Over the past decade, extensive studies have led to the classification of breast tumors into distinct molecular subtypes, allowing subsequent development of efficient targeted treatments for a majority of primary tumors (7) (8) (9) . However, available therapies have limited effect on cancer metastasis and new genetic determinants contributing to essential steps of the metastatic process need to be characterized.
Microtubule (MT)-targeting drugs such as taxanes are used for standard first-line treatment of breast cancer metastasis and new MT-targeting agents, such as epothilones and eribulin, are under clinical evaluation (10) . MTs are polarized and highly dynamic structures that rapidly switch between periods of polymerization (growth) and depolymerization (shrinkage) at the plus ends, a process termed dynamic instability (11) (12) (13) . The extent and rate of MT growth, as well as transitions between growth and shrinkage, are parameters of dynamic instability that can be measured by tracking end-binding (EB) proteins at the MT plus ends (13) (14) (15) ).
Dynamic instability is essential for the MT plus ends to explore the cytosol and ensure cytoskeleton reorganization during cell division and migration. Targeting the expression or activity of metastasis genes that regulate MT dynamics represents a promising option for cancer therapy. Author Manuscript Published OnlineFirst on February 8, 2013 ; DOI: 10.1158/0008-5472. ATIP3 is a MT-associated protein encoded by 8p22 candidate tumor suppressor gene MTUS1 (16-18). We have previously shown that ATIP3/MTUS1 levels are significantly downregulated in 47.7% of invasive breast carcinomas and 62.4% of metastatic tumors (19).
Restoring ATIP3 expression at normal levels in breast cancer cells significantly reduces cancer cell proliferation in vitro and tumor growth in vivo (19). However, effects of ATIP3 on breast cancer metastasis have not yet been evaluated.
In this study, we investigated whether ATIP3 may represent a new biomarker and therapeutic target for breast cancer metastasis. We present evidence that low ATIP3 levels correlate with decreased probability of survival among patients with breast cancer metastasis, and that 
Materials and methods

Breast tumor samples and gene arrays
Microarray data for a series of 150 infiltrating ductal primary breast carcinomas and 11 normal breast tissues from the Institut Curie (Paris) and clinical data for the patients were described elsewhere (19, 20 
Cell lines, plasmid constructs and transfections
Human breast cancer cell lines MDA-MB-468, MCF7 and stable clones were described previously (19). MDA-MB-231-Luc-D3H2LN breast cancer cells (designated D3H2LN) obtained from Caliper Life Science (Xenogen, MA, USA) were derived from an in vivoselected metastatic subclone of MDA-MB-231 cells expressing luciferase and grown as described (23). HeLa cells were provided by Dr. Mounira Amor-Gueret (Institut Curie, specific siRNAs (si#1 and si#2) were performed as described (19) and verified by immunoblotting using anti-MTUS1 polyclonal antibodies (ARP-44419, Aviva Systems, San Diego, CA, USA).
Intracardiac experimental mouse model of metastasis
Experimental metastasis was conducted as described (23, 25, 26) 
Clonogenicity, cell migration and adhesion assays.
Analyses of colony formation, Boyden chambers chemotaxis, trans-endothelial migration, wound healing and cell adhesion were performed as described (23). Time-lapse videomicroscopy analyses of cell motility are described in Supplemental Methods. For cell polarity measurements, transiently transfected D3H2LN were allowed to migrate for 1h30 and analyzed using bright field microscopy. Polarized cells were identified based on nucleus position and cytoplasm extension at the leading edge.
Immunostaining, fluorescence microscopy, analysis of MT dynamics
Cells were plated on glass coverslips and transfected for 24 hrs (plasmids) or 72 hrs (siRNA), fixed in ice-cold methanol for 5 min and incubated for 1 hr at room temperature with anti-α-tubulin clone F2C (27), monoclonal anti-γ-tubulin (Sigma), anti-EB1 (clone 5; BD Bioscience) or anti-acetylated-tubulin (clone 6-11B-1; Sigma). Secondary antibodies and fluorescence images capture are described in Supplemental Methods.
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Linescan analyses of α-tubulin and EB1 fluorescence intensity were done (ImageJ) on a 6 μm line along the length of MT tip. At least 10 MTs per cell in 4 separate cells were measured.
EB1-comet maximal intensity was obtained by subtracting the intensity value of the EB1-dot (100 a.u.) to the maximal staining intensity.
Analyses of MT stability, regrowth, and MT dynamic instability are described in Supplemental Methods.
Statistical analysis
Statistical analyses were done using JMP-7 and GraphPad Prism softwares. OS curves were plotted according to the method of Kaplan-Meier and compared by the log-rank test. Data in bar graphs (mean +/-SD) were analyzed using two-tail unpaired t-test. Dot plot analyses were done using Mann-Whitney test. p<0.05 was considered statistically significant. 
Results
ATIP3 is a prognostic marker of poor outcome in metastatic breast cancer
The prognostic value of ATIP3 as a marker for metastatic progression and overall survival (OS) was evaluated in three independent cohorts of breast cancer patients. Comparison of MTUS1 Affymetrix probeset intensities with clinicopathological data of the patients in a panel of 150 invasive breast carcinomas (Supplementary Table SI) showed that the overall probability of survival is strongly reduced in patients with tumors expressing low as compared to normal ATIP3 transcript levels ( Fig.1A; Supplementary Fig.S1A ). Relapse-free survival (RFS) of the patients was also significantly reduced in low ATIP3-expressing tumors ( Supplementary Fig.S1B ). Similar results were obtained by analyzing MTUS1 levels in an independent cohort of 162 breast cancer patients (Fig.1B , Supplementary Table SII) and in a meta-analysis of 2898 breast cancer patients ( Fig.1C; Supplementary Fig.S1C, S1D ). Of note, correlation between ATIP3 expression and OS of the patients was independent of the estrogen receptor (ER) status of the tumor (Fig.1D ).
Tumors were then classified according to their metastatic properties and MTUS1 probeset intensities were compared with the probability of patient survival. As shown in Fig.1E , the percentage of patients with metastatic disease surviving after 5 years was markedly reduced when tumors expressed low ATIP3 (6.25%) compared to normal ATIP3 levels (31.6%) whereas in patients with non-metastatic tumors, 5-years survival (Fig.1E, Supplementary   Fig.S1E ) and OS rates (Fig.1F, 1H) were independent of the levels of ATIP3. Within patients with metastatic disease, OS rates (Fig.1F, 1H, Supplementary Fig.S1E ) and survival time (Fig.1G, 1I ) were also reduced when tumors expressed low levels of ATIP3. Thus, ATIP3
expression is an important indicator of clinical outcome for patients with metastatic breast tumors. Correlation between low ATIP3 levels and reduced survival rates among patients with advanced breast cancer suggests major effects of ATIP3 on metastatic progression. 
ATIP3 limits breast cancer metastatic colonization in vivo
In vivo effects of ATIP3 on the metastatic potential of breast cancer cells were evaluated using a well-defined experimental mouse model of metastasis monitored by intravital bioluminescence imaging (23, 25, 26). Highly metastatic, ATIP3-negative, D3H2LN breast cancer cells were transfected with either GFP or GFP-ATIP3 and independent stable cell clones (Cl3, Cl6) expressing moderate levels of ATIP3 were selected ( Fig.2A, left) . All cell clones exhibited similar levels of luciferase activity ( Fig.2A, right) . Metastatic cancer cells were injected intracardiacally into the bloodstream of nude mice in order to recapitulate the late, rate-limiting, steps of the metastatic process, and examine metastatic dissemination to various organs while avoiding any effect of ATIP3 on primary tumor growth. Four groups of 18 mice were analyzed in two independent experiments. For each animal, the total number of metastatic foci and the number of photons/sec were quantified every two days for 24 days (Supplementary Table SIII 
ATIP3 impairs breast cancer cell proliferation and migration
Metastatic colonization involves cancer cell migration, invasion through the extracellular matrix and proliferation at the secondary site. As expected from our previous studies (19), cell proliferation was significantly reduced in ATIP3-positive clones Cl3 and Cl6 as compared to control ( Supplementary Fig.S3A ). In addition, Boyden chambers assays of chemotaxis and invasion revealed more than 90% reduction in the pro-migratory properties of Cl3 compared to GFP (Fig.3A) . Similar effects were observed using stably transfected MDA-MB-231 cells ( Supplementary Fig.S3B ). Conversely, ATIP3-silencing in metastatic MDA-MB-468 breast cancer cells expressing endogenous ATIP3 induced a 2 to 2.5-fold increased chemotactic migration ( Fig.3B ), suggesting that cancer cells having lost ATIP3 may acquire a promigratory phenotype and may be more prone to develop distant metastasis.
The ability to migrate through a monolayer of endothelial cells (trans-endothelial migration) was significantly reduced (58±16%) in Cl3 compared to control (Fig.3C) . Adhesion of clones Cl3 and Cl6 to endothelial cells was significantly elevated (3-fold and 2.8-fold, respectively) compared to WT (Fig.3D) , suggesting that increased tumor-endothelial cell adhesion may account for reduced trans-endothelial migration. Cell adhesion to collagen I was also increased in Cl3 (1.85-fold) and Cl6 (1.93-fold) compared to WT ( Fig.S3F ), further confirming the inhibitory effect of ATIP3 on cancer cell migration.
ATIP3 alters microtubule dynamics
We hypothesized that ATIP3, being closely associated with microtubules (19), may limit cell proliferation and migration by regulating MT dynamics. We first analyzed the consequences of ATIP3 depletion on the sensitivity of MTs to nocodazole, that prevents repolymerization of Fig.S4A ). In ATIP3-depleted HeLa cells, significantly more EB1 comets of increased length and intensity were detected compared to control cells (Fig.5B) , suggesting that ATIP3 silencing increases MT dynamics. Time-lapse TIRF videomicroscopy analysis of EB1-GFP comets (movie 5) and subsequent MT-tips tracking indicated that MT growth episodes were significantly longer in ATIP3-silenced HeLa cells compared to control (Fig.5C ). ATIP3-depletion increased MT growth rate and decreased the time spent in pause as well as the frequency of catastrophes (Fig.5C ), accounting for increased MT dynamics. Conversely, videomicroscopy of EB3-GFP comets following expression of mCherry-ATIP3 in MRC5-SV cells (movie 6), and corresponding kymographs ( Supplementary Fig.S4B ), indicated that ATIP3 expression decreases MT dynamics and reduces the rate of MT growth.
MT stabilization and decreased growth rate at the cell periphery should be responsible for an inhibition of MT targeting and capture at the cell cortex (30) . As shown in Fig.5D , in migrating D3H2LN cells MTs projected radially toward the cell periphery and MT plus ends were close to the cell edge (mean distance 1.43 ± 0.7 μm) whereas in the presence of ATIP3, 
MTs were bended and more than 50% of MT tips did not reach the cell margin (mean distance 2.31 ±1.2 μm). Of note, reduced ability of MTs to reach the cell cortex in migrating ATIP3-positive cells was accompanied by a 34% decrease in cell polarity (Fig.5E ). Taken together, these results suggest that ATIP3-dependent regulation of MT dynamics results in decreased ability of microtubules to reach the cell cortex, which contributes to reduced cell polarity and migration.
MT-binding domain D2 recapitulates the functional effects of ATIP3
The ATIP3 polypeptide was cleaved into three fragments designated D1, D2 and D3 (Fig.6A) which were fused to GFP and expressed in RPE-1 cells (Fig.6B ). As shown in Fig.6C , the GFP-D1 fusion protein did not associate with MTs and was rather diffuse in the cytosol.
Accordingly, GFP-D1 expression had no significant effect on the number, size or intensity of EB1 comets (Fig.6D) . In contrast, GFP-D2 clearly colocalized with the microtubule cytoskeleton and centrosome in living cells (Fig.6C) . As for GFP-ATIP3, GFP-D2 was entirely retrieved in the pellet fraction in MT co-sedimentation assays ( Supplementary   Fig.S5A ). Of interest, upon expression of GFP-D2, accumulation of EB1 as comet-like structures at the MT plus ends was strongly impaired (Fig.6E) , indicating that expression of the D2 domain is sufficient to stabilize microtubules. Expression of GFP-D3 (Fig.6C ) led to the formation of large aggregates containing tubulin, probably due to oligomerization of coiled-coil motifs present in the C-terminal region of ATIP3 (31) . Because of these aggregates, functional properties of GFP-D3 could not be evaluated further.
Altogether our results identify D2 as the ATIP3 domain able to associate with MTs and suppress their dynamics. Of importance, the D2 domain also retained the ability of ATIP3 to inhibit cell proliferation (91.6% inhibition for GFP-D2 and GFP-ATIP3 compared to GFP) (Fig.7A) . In wound healing assays, cells expressing GFP-D2 showed reduced cell migration and directionality (Fig.7B) similar to GFP-ATIP3, GFP-D2 positive cells mostly remained at the back of the wound and were overtaken by untransfected cells (Fig.7C, Supplementary Fig.S5B) 
Discussion
We report here that ATIP3 is an important prognostic marker for survival of the patients with breast cancer, independently of the ER status of the tumor. Using three different patient cohorts, we show that among metastatic breast tumors, low ATIP3 levels correlate with reduced probability for overall survival of the patients, suggesting that ATIP3 may be an important indicator of metastatic progression. Examination of ATIP3 levels in breast tumors may contribute to identify a population of patients at high risk of fatal complication, who should be the subject of careful medical follow-up. At the molecular level, we show that ATIP3 is a microtubule-associated protein with potent MT-stabilizing effects. We propose that by stabilizing MTs, ATIP3 decreases their dynamics therefore leading to impaired ability of MT tips to reach the cell cortex during migration. MT dynamics at the cell cortex is essential for generating a polarized MT array, required for cell polarity and migration (30) . Reduced MT dynamics may thus represent a major mechanism accounting for anti-migratory and anti-metastatic effects of ATIP3 in breast cancer. 
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